中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2015年
16期
2461-2463
,共3页
重组人血小板生成素%重组人白介素-11%白血病%化学治疗%血小板减少症
重組人血小闆生成素%重組人白介素-11%白血病%化學治療%血小闆減少癥
중조인혈소판생성소%중조인백개소-11%백혈병%화학치료%혈소판감소증
Human recombinant platelet hormone (rhTPO)%Recombinant human interleukin -11 (rhIL -11)%Leukemia%Chemotherapy%Thrombocytopenia
目的：观察重组人血小板生成素（rhTPO）用于急性白血病化疗后血小板减少症的临床治疗效果，并探讨其安全性。方法选择急性白血病化疗后血小板减少症患者80例，按就诊顺序登记编号，并按照单双号随机分为研究组与对照组，每组各40例。对照组应用重组人白介素11（rhIL-11）治疗，研究组应用rhTPO 治疗，检测两组血小板（PLT）等指标变化，并观察不良反应等。结果研究组 PLT 恢复最大值为（217.4±52．7）×109／L，明显高于对照组，差异有统计学意义（t ＝15．63，P ＜0．05）；研究组化疗后 PLT 恢复至100×109／L 时间为（15．6±3．6）d，明显短于对照组，差异有统计学意义（t ＝10．72，P ＜0．05）；研究组不良反应发生率为12．5％，低于对照组的35．0％，差异有统计学意义（χ2＝9．87，P ＜0．05）。结论rhTPO 治疗急性白血病化疗后血小板减少症效果优于 rhIL-11，能够显著改善患者血小板减少状况，不良反应较少，安全性更高，值得临床推广与应用。
目的：觀察重組人血小闆生成素（rhTPO）用于急性白血病化療後血小闆減少癥的臨床治療效果，併探討其安全性。方法選擇急性白血病化療後血小闆減少癥患者80例，按就診順序登記編號，併按照單雙號隨機分為研究組與對照組，每組各40例。對照組應用重組人白介素11（rhIL-11）治療，研究組應用rhTPO 治療，檢測兩組血小闆（PLT）等指標變化，併觀察不良反應等。結果研究組 PLT 恢複最大值為（217.4±52．7）×109／L，明顯高于對照組，差異有統計學意義（t ＝15．63，P ＜0．05）；研究組化療後 PLT 恢複至100×109／L 時間為（15．6±3．6）d，明顯短于對照組，差異有統計學意義（t ＝10．72，P ＜0．05）；研究組不良反應髮生率為12．5％，低于對照組的35．0％，差異有統計學意義（χ2＝9．87，P ＜0．05）。結論rhTPO 治療急性白血病化療後血小闆減少癥效果優于 rhIL-11，能夠顯著改善患者血小闆減少狀況，不良反應較少，安全性更高，值得臨床推廣與應用。
목적：관찰중조인혈소판생성소（rhTPO）용우급성백혈병화료후혈소판감소증적림상치료효과，병탐토기안전성。방법선택급성백혈병화료후혈소판감소증환자80례，안취진순서등기편호，병안조단쌍호수궤분위연구조여대조조，매조각40례。대조조응용중조인백개소11（rhIL-11）치료，연구조응용rhTPO 치료，검측량조혈소판（PLT）등지표변화，병관찰불량반응등。결과연구조 PLT 회복최대치위（217.4±52．7）×109／L，명현고우대조조，차이유통계학의의（t ＝15．63，P ＜0．05）；연구조화료후 PLT 회복지100×109／L 시간위（15．6±3．6）d，명현단우대조조，차이유통계학의의（t ＝10．72，P ＜0．05）；연구조불량반응발생솔위12．5％，저우대조조적35．0％，차이유통계학의의（χ2＝9．87，P ＜0．05）。결론rhTPO 치료급성백혈병화료후혈소판감소증효과우우 rhIL-11，능구현저개선환자혈소판감소상황，불량반응교소，안전성경고，치득림상추엄여응용。
Objective To study the efficacy of recombinant human thrombopoietin (rhTPO)for the treat-ment of chemotherapy -induced thrombocytopenia with leukemia.And to explore its security.Methods 80 thrombo-cytopenia of acute leukemia after chemotherapy were selected.All patients were randomly divided into the research group and the control group according to the single and double of order registration number in clinic,40 cases in each group.The control group was treated with recombinant human interleukin -11 (rhIL -11),the research group was applied rhTPO treatment.The platelet (PLT)level of two groups,and other indicators of change were detected,and adverse reactions were observed.Results PLT resuming maximum value of the research group was (217.4 ±52.7) ×109 /L,which was significantly higher than the control group,the difference was statistically significant (t =15.63, P <0.05).The time of PLT recovery to 100 ×109 /L of the research group after chemotherapy was (15.6 ±3.6)d, which was significantly lower than the control group,the difference was statistically significant (t =10.72,P <0.05). The adverse reactions incidence of the research group was 12.5%,lower than 35.0% of the control group,the differ-ence was statistically significant (χ2 =9.87,P <0.05).Conclusion The treatment effect of RhTPO for thrombocy-topenia of the acute leukemia after chemotherapy is better than that of rhIL -11,can significantly improve the throm-bocytopenia,and has less adverse reaction and higher security.It is worthy of clinical popularization and application.
